104266-90-2

Basic information

• Product Name: 4-Benzyl-3-(3-methyl-butyryl)-oxazolidin-2-one
• Synonyms: 3-(3-Methyl-1-oxobutyl)-4-(p henylMethyl)-, (S)-2-Oxazolidinone;2-Oxazolidinone, 3-(3-Methyl-1-oxobutyl)-4-(phenylMethyl)-, (S)-;(S)-4-benzyl-3-(3-Methylbutanoyl)oxazolidin-2-one;(4S)-4-Benzyl-3-isovaleryloxazolidin-2-one;2-Oxazolidinone, 3-(3-methyl-1-oxobutyl)-4-(phenylmethyl)-, (4S)-;4S-Benzyl-3-(3-methyl-butyryl)-oxazolidin-2-one;4-Benzyl-3-(3-methyl-butyryl)-oxazolidin-2-one;(S)-3-(3-Methylbutanoyl)-4-benzyloxazolidin-2-one
• CAS NO: 104266-90-2
• Molecular Formula: C₁₅H₁₉NO₃
• Molecular Weight: 261.32
• Product Categories: Heterocyclic Building Blocks
• Mol File: 104266-90-2.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 412.912 °C at 760 mmHg
• Flash Point: 203.522 °C
• Appearance: /
• Density: 1.152 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -2.33±0.40(Predicted)
• CAS DataBase Reference: 4-Benzyl-3-(3-methyl-butyryl)-oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzyl-3-(3-methyl-butyryl)-oxazolidin-2-one(104266-90-2)
• EPA Substance Registry System: 4-Benzyl-3-(3-methyl-butyryl)-oxazolidin-2-one(104266-90-2)

Safety Data

• Statements: 36-43
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 104266-90-2(Hazardous Substances Data)

Usage

Uses

(4S)-4-Benzyl-3-isovaleryloxazolidin-2-one is an intermediate in the preparation of orally active renin inhibitor Aliskiren (A536000).

InChI:InChI=1/C15H19NO3/c1-11(2)8-14(17)16-13(10-19-15(16)18)9-12-6-4-3-5-7-12/h3-7,11,13H,8-10H2,1-2H3/t13-/m0/s1

Upstream product

• 134807-37-7 (4S)-3-((2S)-4-(tert-butoxy)-2-(1-methylethyl)-4-oxobutanoyl)-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 100-51-6 benzyl alcohol 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 63-91-2 L-phenylalanine 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 108-12-3 isopentanoyl chloride 
• 90719-30-5 (4S)-3-((E)-2-butenoyl)-4-benzyl-2-oxazolidinone 
• 1184-58-3 dimethylaluminum chloride 
• 503-74-2 3-methylbutyric acid 

Downstream Products

• 191664-12-7 N-[(R)-2-((S)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-3-methyl-butyl]-benzamide 
• 172900-80-0 2(R)-isopropyl-3-(p-tert-butyl-phenyl)-propanol 
• 117037-09-9 (S)-4-Benzyl-3-((S)-2-benzyl-3-methyl-butyryl)-oxazolidin-2-one 
• 240821-65-2 (4S)-3-[(2S)-2-(1-methylethyl)-1-oxopent-4-en-1-yl]-4-(phenylmethyl)oxazolidin-2-one 
• 470454-06-9 4-(R)-benzyl-3-(2-(R)-benzyloxymethyl-3-methylbutyryl)oxazolidin-2-one 
• 150615-46-6 (S)-4-benzyl-3-[(R)-2-hydroxymethyl-3-methylbutanoyl]oxazolidinone 
• 919995-31-6 trans-1-bromo-6-[4-(S)-benzyl-2-oxo-oxazolidin-3-yl]-(S)-isopropyl-hex-2-en-6-one 
• 919995-32-7 trans-1-[4-(S)-benzyl-2-oxo-oxazolidin-3-yl]-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-2(S)-7(S)-diisopropyl-oct-4-en-1,8-dione 
• 324519-70-2 C₁₈H₂₂ClNO₃ 
• 1187941-31-6 C₂₆H₃₁NO₄ 
• 1322077-39-3 C₅₁H₆₇NO₉S 
• 1322077-41-7 C₂₆H₄₀O₇ 
• 1351987-42-2 C₂₆H₃₉NO₆ 
• 1236549-00-0 {(1S,3S)-1-((2S,4S)-4-isopropyl-5-oxo-furanidin-2-yl)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-pentyl}-carbamic acid benzyl ester 

Relevant articles and documents

A Facile, Six-Step Process for the Synthesis of (3 S,5 S)-3-Isopropyl-5-((2 S,4 S)-4-isopropyl-5-oxo-tetrahydrofuran-2-yl)-2-oxopyrrolidine-1-carboxylic Acid tert -Butyl Ester, the Key Synthetic Intermediate of Aliskiren

A facile, six-step process for the synthesis of (3S,5S)-3-isopropyl-5-((2S,4S)-4-isopropyl-5-oxotetrahydro- furan-2-yl)-2-oxopyrrolidine-1-carboxylic acid tert-butyl ester from (S)-4-benzyloxazolidin-2-one 2 in an overall 50% yield is reported. The key transformations include: a highly efficient diastereoselective epoxidation, Lewis acid-catalyzed ring-opening with bromide, an SN2 reaction using NaN3, and a tandem reduction-cyclization reaction.

JAK INHIBITORS

Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

JAK INHIBITORS

Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.